3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
114
Neoplasms
28
Lung Neoplasms
24
Non-Squamous Non-Small Cell Lung Cancer
21
Pancreatic Neoplasms
13
Colorectal Neoplasms
6
Neoplasm Metastasis
5
Breast Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Lymphoma
3
Thoracic Neoplasms
2
Solid Tumors
2
Recurrence
2
Neoplasms by Site
2
Lung Diseases
2
Familial ependymoma
2
Ependymoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Bronchial Neoplasms
2
Advanced Solid Tumors
2
Vascular Diseases
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoking
1
Small Cell Lung Carcinoma
1
Interventions
Carboplatin
3
motexafin gadolinium
2
figitumumab
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
Paclitaxel
2
Docetaxel
2
vandetanib
1
tanespimycin
1
Vinorelbine
1
Temozolomide
1
Pemetrexed
1
Gemcitabine
1
Everolimus
1
Erlotinib Hydrochloride
1
Crizotinib
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Large Cell
×
Erlotinib Hydrochloride
×
Clear all
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts